Drug-drug interactions (DDIs) are a major cause of adverse drug effects and a public health concern, as they increase hospital care expenses and reduce patients' quality of life. DDI detection is, therefore, an important objective in patient safety, one whose pursuit affects drug development and pharmacovigilance. In this article, we describe a protocol applicable on a large scale to predict novel DDIs based on similarity of drug interaction candidates to drugs involved in established DDIs. the method integrates a reference standard database of known DDIs with drug similarity information extracted from different sources, such as 2D and 3D molecular structure, interaction profile, target and side-effect similarities. the method is interpretable in that it generates drug interaction candidates that are traceable to pharmacological or clinical effects. We describe a protocol with applications in patient safety and preclinical toxicity screening. the time frame to implement this protocol is 5-7 h, with additional time potentially necessary, depending on the complexity of the reference standard DDI database and the similarity measures implemented.
IntroDuctIon
DDIs cause up to 30% of adverse drug effects (ADEs) 1, 2 , and adverse events are one of the primary reasons that drugs fail clinical trials 3 . Moreover, in a study published in 2007 assessing the effects of DDIs 4 , they were estimated to be responsible for 0.57-4.8% of all hospital admissions. As a result, DDIs are a drain on public health, costing billions of dollars and reducing patients' quality of life. The detection and preclinical prediction of DDIs remains an open research challenge with a broad effect on both drug development and pharmacovigilance. The design of tools to help study possible DDIs is of great interest to pharmaceutical companies, regulatory authorities, such as the US Food and Drug Administration (FDA) 3, 5 , as well as to many researchers working in a variety of fields including absorption, distribution, metabolism and excretion (ADME) properties, computational biology, translational medicine and pharmacovigilance.
DDIs can occur any time a patient is taking more than one drug concurrently and may occur at the pharmacokinetic level (i.e., ADME properties) or at the pharmacodynamic level (i.e., drugs targeting the same pharmacological receptor or targeting related pathways). As a result, DDIs may manifest as a reduction in efficacy or as an increased toxicity of the drugs. The final action can be synergistic, antagonistic or coalistic-whereby a new effect is produced that is not associated with either drug taken individually.
Although DDIs are evaluated during drug development, many of them go undetected owing to the limited number of participants in clinical trials and the high number of drugs and combinations that result from these trials. DDIs are also studied when drugs enter the marketplace. However, multiple drug combinations and the presence of different comorbidities and confounding factors make the task of detecting DDIs difficult. Depending on the severity of the DDI, regulatory authorities such as the FDA can adopt different measures to address it, from the introduction of a warning in the label of a drug involved in the DDI to the drug's withdrawal from the market.
We describe herein a protocol for multitype DDI prediction that can facilitate and improve DDI detection. This approach can generate sets of potential DDI candidates for both pharmacokinetic and pharmacodynamic interactions. The set of new potential DDIs could be used to filter out candidates extracted from pharmacovigilance databases, such as Electronic Health Records, and to strengthen the signals obtained through data mining 6, 7 .
This protocol, whose workflow is outlined in Figure 1 , provides a detailed description of the different steps involved in integrating drug information data. The protocol is generalizable and can be implemented using sources of data other than those described in the PROCEDURE, from other well-established DDI sources to drug similarity measures not used in this protocol. In fact, we have been working on the development of this type of DDI predictor using three different similarity measures: 2D and 3D molecular structure approaches, and interaction profile similarity [8] [9] [10] . In this article, we increased the number of similarity measures by introducing in the DDI predictor information related to target and adverse-effects similarities.
Integrated workflow for the multitype DDI predictor
An overview of the general protocol is provided in Figure 1 . The protocol involves the generation of the reference standard DDI database (matrix M 1 ) and the drug similarity databases (matrix M 2 ). These data are integrated through a straightforward process consisting of the extraction of the maximum value in each array of the matrix multiplication to generate the set of potential new DDIs (matrix M 3 ). The last stage of the protocol is the further assessment of the performance of the final model.
Similarity-based modeling in large-scale prediction of drug-drug interactions

Generation of the reference standard DDI database (matrix M 1 ).
This stage is the first in the development of the protocol. In the approach delineated here, the DDI database is downloaded from DrugBank (http://www.drugbank.ca/) using the Interax Interaction Search module and transformed in a matrix, M 1 , with binary values (1, 0) , representing the interaction between two drugs and their lack of interaction, respectively. As part of the analysis, the pharmacological or clinical effects associated with the DDIs are annotated.
Generation of the drug similarity databases (matrix M 2 ).
In this second stage of the protocol, similarity data are calculated through the implementation of three substages: calculation of the similarity measure, computation of similarity between drugs pairs and final construction of the matrix M 2.
Calculation of similarity measures. Different similarity measures can be calculated for all the drugs included in the study and integrated in the system, in particular measures such as 2D structural fingerprints, interaction profile fingerprints (IPFs), target profile fingerprints, ADE profile fingerprints and 3D pharmacophoric approaches.
The basic 2D molecular structure fingerprint technique consists of representing a molecule as a bit vector that codifies the presence or absence of different substructural or pharmacophoric features in each bit position. In the development of this protocol, we used MACCS (for Molecular Access System) structural keys 11 , although other types of 2D or 3D molecular fingerprints could equally be used. MACCS codifies 166 structural keys in bit positions. As an example, some structural keys in the MACCS fingerprint for the drug diazepam (Fig. 2) are as follows: bit 19 (seven-member ring), bit 78 (C=N group), bit 92 (OC(N)C group) and bit 163 (six-member ring). In Figure 2 , only a small representation of the structural keys included in MACCS for the drug diazepam is reported. As a way to represent a sparse binary vector, only the positions codifying the fragments present in the molecule are stored in the final fingerprint.
Another similarity measure that can be integrated in the development of the DDI predictor is an IPF 9 . The design of an IPF is similar to that of a molecular structure fingerprint, but instead of codifying substructural features in each bit position of the vector, an IPF codifies the different drug interactions described for a particular drug (Fig. 3) . Through IPF, two drugs can be compared on the basis of the similarities between their individual drug interaction profiles. The same idea can be expanded to codify, for each drug, its known targets (target fingerprints) or the adverse effects already described (ADE fingerprints) 12, 13 . In Figure 3 , three different drug fingerprints that can be calculated to determine the level of similarity between drugs are represented.
The calculation of 3D molecular structure information follows a different, more complex scheme. The idea in this case is to use the 3D structure of each drug included in the study as a template and to identify other drugs with similar shape and electrostatic properties through pharmacophoric shape screening 14 . The alignment of the structures is based on the identification of atom triplets and the use of a pairwise atom distance distribution approach. However, different conformational analysis, alignment algorithms and software packages can be used and implemented in the protocol.
Computation of similarity between drugs. In this protocol the Tanimoto coefficient (TC) is used to quantify and compare drug similarity using the different measures, including MACCS, IPFs, target fingerprints and ADE fingerprints. The TC is also known by the term Jaccard index. The TC can adopt values in the range between 0 (maximum dissimilarity) and 1 (maximum similarity). The TC between fingerprints A and B is defined as follows:
In the formula, N A and N B is the number of features present in fingerprints A and B, respectively, and N AB is the number of features present in common to both fingerprints A and B. In the case of two 'identical' drugs, TC is 1 (N A = N B = N AB ), whereas if there is no fingerprint overlap between drugs TC is 0. In the case of the similarity measure based on the 3D pharmacophoric approach, once the alignment between the drug structures is made, i.e., the shape of query drug A and that of drug B being screened, it is possible to calculate a similarity scoring (Phase Sim property-Sim(A,B)) by calculating the overlapping volume between pharmacophoric features (Phase package, version 3.3; http://www.schrodinger.com). As for TC, the Phase Sim property ranges in value between 0 (minimum similarity) and 1 (maximum similarity) and is a function of the overlap 
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( , ) max( ( , ), ( , )) = Construction of the matrix M 2 . The third stage in the generation of the M 2 matrix consists in arranging the data into the said matrix M 2 , so that each cell represents the similarity between the corresponding pair of drugs. In the present protocol, five possible M 2 matrices are calculated and weighed with each of the five described similarity measures.
Generation of the new set of potential DDIs (matrix M 3 ).
In this stage of the protocol, the two databases M 1 and M 2 are integrated. The objective here is to obtain the matrix M 3 that contains all the possible scored DDIs through the multiplication of M 1 by M 2 retaining only the highest value in the array multiplication in each cell (the complete process is explained in the PROCEDURE). In the final stage of the protocol, it is possible to associate clinical effects with the new DDIs.
Assessment of the model performance.
A simple validation to assess the performance of the protocol consists in plotting the receiver operating characteristic (ROC) curve. In ROC curves, the true positive fraction (sensitivity) is plotted against the false positive fraction (1 -specificity). The area under the curve (AUROC) can have values between 1 (perfect classifier) and 0.5 (random classifier). In our case, to plot the ROC curve, we considered the initial well-established DrugBank interactions (reference standard) as true positives and the remaining protocol-generated DDI candidates that are actually not contemplated as existing DDIs by the DrugBank database itself as false positives. Statistical measures, such as sensitivity, specificity, precision and enrichment factor, could also be calculated to evaluate performance. However, a more complete assessment of the performance of the model can be carried out in external tests that are used to determine whether the data introduced in the model are representative enough to predict DDIs reported in data sources other than the DrugBank. It is convenient to test models using a cross-validation approach, i.e., transferring 25% of the DDIs reported in the data source to a test set (the 'hold-out' validation set) and constructing the model with the remaining 75% of the DDIs, and an approach that makes use of external test sets (i.e., provided by additional reference standard sources, such as Micromedex (http://www. micromedexsolutions.com)).
Characteristics, caveats and limitations
A prerequisite for the implementation of this protocol is to have a reference standard database with well-established DDIs. On the basis of these data, and through the integration of drug similarity information, the protocol relies and expands on a pattern of interactions that are already detectable in the initial reference standard DDI data, i.e., similar drugs have similar drug interactions. For this reason, a limitation of the present approach resides in the comprehensiveness of the initial standard DDI data used to construct it. The model performance is expected to be limited if we analyze DDIs with no representation in the initial database. The example procedure reported below makes use of the DDI DrugBank database, but additional data from large DDI sources could be used to increase the generality of the approach.
Prediction models developed using this protocol showed great robustness in hold-out validation sets. As described by our research group 8, 9 , the DDI-predicting models were generated with 85%, 70% and 55% of the initial DDI reference standard, whereas the remaining 15%, 30% and 45% of the DDIs, respectively, were used as (hold-out) validation data sets. The performance of the models in the different sets was barely affected by the partition of the initial reference standard. As an example, in a protocol including 928 drugs involved in 9,454 interactions, and using MACCS fingerprints as a similarity measure 8 , sensitivity was 0.68 and specificity was 0.96 (100% of the DDI reference standard in the training). The models generated by implementing a protocol after 45% of the interactions were removed from the initial data set (to be used as the hold-out set) showed metrics very close to those of the initial system 8 : sensitivity and specificity in the training data set-the one including 55% of the data set interactions-was 0.54 and 0.96, respectively; when evaluating the hold-out validation set, sensitivity was 0.56 and specificity was 0.96. It is worth noting, however, that the method's selection to define the different hold-out sets was random; if the method takes into account selectively all the drugs included in defined pharmacological categories, the performance of the final system will be negatively affected by the division of different sets of DDIs. This decrease in performance is due to the fact that not enough representative interaction data will be available in the reference standard to try and predict successfully the interactions for a particular drug class in the hold-out set.
The protocol described in this article is designed to be used on a large scale. The generation of a large list of drug pair candidates along with the associated biological or clinical effect is a useful resource to be combined with other methodologies of large-scale analysis, such as Electronic Health Records data mining, to improve signal detection steps. For this reason, the workflow described herein is not suitable for the detection of small variations in the similarity measure that can strongly affect the biological effects of the drugs. As an example, different biological outcomes caused by small variations in the molecular structure could go undetected after implementation of the present protocol. However, some similarity measures could be more suitable than others to detect DDI risks in the same category of drugs. The implementation of the present protocol generates new DDI candidates that belong to two different categories: (i) a new pair of DDI candidates is generated by comparing two drugs that belong to the same pharmacological category, i.e., an initial A-B interaction generates a predicted A-C interaction, when B and C are in the same pharmacological class; and (ii) the predictor generates new DDI candidates comparing two drugs belonging to different pharmacological classes. DDI candidates belonging to the first category are likely to be generated when the TC value is very high, i.e., the first DDI candidates highlighted by the model with the best score (TC values). The information provided by the predictor in this case is more obvious and rather predictable. However, the model is still useful to scientists with no pharmacological background. The generation of DDI candidates belonging to the second category is more frequent as the TC value decreases. Although the certainty of the DDI and the associated effect is lower in the second category (higher likelihood of false positive DDIs), the new DDI candidates are more unexpected and challenging than those belonging to the first category.
The above-mentioned ability of this protocol to enable researchers to detect similarities between drugs in the same or different pharmacological classes is also related to the similarity measure implemented in the predictor. In this protocol, M 2 is constructed by introducing different types of similarity measures between drugs: 2D and 3D molecular structure similarity, interaction profile similarity, target profile similarity and adverse event profile similarity. A limitation in the predictor could be the 'upstream' bias introduced with the information provided in the construction of the similarity measurement. This biased information could, for example, consist of similarity measures, such as the interaction profile, target or side effects, calculated through knowledge databases such as DrugBank (http://www.drugbank. ca) or SIDER (http://sideeffects.embl.de/).
Information included in the data sources used to calculate the similarity measures could be highly influenced by pharmacological classification that is biased or dependent on possibly partial available information. For this reason, although they can detect interclass similarity, these measures could have a tendency to capture intraclass drug similarity with high scores. Moreover, as we point out in the ANTICIPATED RESULTS, DDI predictors based on knowledge measures performed well in our test detecting differences in drug-specific interaction risks for drugs belonging to the same pharmacological category. Notably, however, although 2D and 3D molecular structure methodologies offer the opportunity to capture molecular similarities between drugs in the same pharmacological class, they also potentially enable researchers to detect high similarity between pairs of drugs that belong to different pharmacological categories (interclass similarity). As mentioned above, this ability to detect interclass similarity has the potential of pointing out challenging and unexpected DDI candidates. Moreover, knowledge-dependent similarity measures cannot be applied to drugs for which no relevant information is available-that is, it cannot be applied to drugs that have been recently introduced in the market, for which limited target or adverse event profile information exists.
The integration in the analysis of other types of similarity measures or the implementation of a complex and common measure with information from all the similarity estimation approaches may improve the results and contribute to making this protocol more robust.
Other methods to discover DDIs Different methodologies have been described to identify and analyze new DDI candidates, including pharmacokinetic and pharmacodynamic interactions. Metabolism-related interactions have a relevant clinical impact. In fact, cytochrome P450 (CYP) enzymes are responsible for the metabolism of many drugs. Different approaches have been developed to identify DDIs between CYP-metabolized drugs, which are approaches that integrate in vitro data to predict in vivo (animal and human) CYPmediated interactions 15 . Computational modeling has also been used to predict CYP metabolism-based DDIs 16 . Other pharmacokinetic processes, such as absorption, distribution or excretion, could be of interest from the point of view of DDI prediction 17 . Some researchers have also studied pharmacodynamic interactions and their mechanisms using response surface analysis 18 .
Informatics has an important role in the discovery of new DDIs. Cheminformatic methods, such as 2D/3D quantitative structure-activity relationships (QSAR) and molecular docking, can be useful to predict DDIs [19] [20] [21] . In contrast, data mining of scientific literature, electronic medical records or adverse event databases is an emergent approach for DDI detection 2, [22] [23] [24] . In a manner similar to the present protocol, a large-scale method was also published on the basis of the integration of similarity measures with knowledge DDI databases 25 . Our research group has also introduced large-scale DDI predictors based on similarity measures [8] [9] [10] . The novelty of the present protocol resides in the simplicity of the database integration and the pharmacological effects associated with the final candidates. An important feature of our approach is that it is a multi-type predictor that can isolate the pharmacological or clinical effect associated with the predicted interactions.
Experimental design
In the implementation of the protocol and calculation of similarity measures, i.e., 2D molecular fingerprints, molecular modeling packages, such as Molecular Operating Environment (MOE; http://www.chemcomp.com/), or free open-source initiatives, such as Open Babel (http://www.openbabel.org/) and Python (https:// www.python.org/), can be used. Both procedural routes are good alternatives for the similarity measures calculation. MOE also provides a tool for performance analysis through ROC curves. However, the use of some free packages, such as R (http://www. r-project.org), could be a great multifunctional tool with interesting options for calculating multiple ROC curves and confidence intervals. The order in which the fingerprint calculations should be carried out is not definite, and the order laid out in the PROCEDURE is not mandatory. Similarity measure selection criteria could be dependent on the characteristics of the study, and only one similarity measure can be implemented in the development of the protocol. 
MaterIals
EQUIPMENT
Computational requirements
Computer: the DDI model can be developed using a computer with Windows, OS X or Linux/Unix operating systems, with no special memory requirements Software: although different software packages can be used for this protocol, the PROCEDURE is implemented using the molecular modeling software MOE 2011. 
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this script generates an output .csv file containing all pairwise TCs above a specified cutoff (T_CUTOFF, default 0.45). TCs are calculated using Open Babel and MACCS fingerprinting (http://openbabel.org/docs/dev/Features/Fingerprints.html). The fingerprint can be changed by specifying a different string for FINGERPRINT. Available fingerprints are FP2, FP3, FP4 and MACCS. proceDure Generation of the reference standard DDI database (matrix M 1 ) • tIMInG <4 h 1| Use the Interax Interaction Search module in the DrugBank database to check for interactions between different drugs at the same time. Save the DDIs found in DrugBank into a tab-separated file containing three columns: the first column, 'Drug A', will contain the generic names of all drugs involved in DDIs according to the database; the second column, 'Drug B', will contain the generic names of the same set of drugs reported in the relevant order according to the known interactions; and the third column will contain the description of the effect produced by the interaction; see table 1 for an example of how this file should look like.  crItIcal step It is worth noting that all the interactions should appear twice in the file, as the drugA-drugB interaction is the same as that for drugB-drugA. The presence of these repetitions is important to generate a symmetric M 1 matrix.
fingerprint_file.fpt example ----------------------------
2| List the drugs in column A and in row 1 of an Excel worksheet.
3| Use the function '=concatenate' as described in Figure 4 to bind the drug names. 4| Substitute the interactions described in each cell and also present in the initial list with '1', so as to indicate that a particular cell contains a DDI described in the initial DrugBank database. Place a '0' in all cells representing 'interactions' not actually existing according to the DrugBank list. Through this process, the researcher will generate the matrix M 1 , with binary values, 1 and 0, representing the interaction between two drugs and their noninteraction, respectively.  crItIcal step Make sure that matrix M 1 thus obtained is symmetrical and contains the same interactions A-B and B-A in the relevant cells.
calculation of similarity measures and tcs between drugs (matrix M 2 ): 2D Maccs fingerprints
• tIMInG <1 h  crItIcal Please note that the instructions provided in the main PROCEDURE are given with the assumption that the researcher will use the MOE software. However, open-source software can also be used for the purpose of fingerprint and TC calculation. In Box 1, we provide directions to be implemented in Python to calculate MACCS fingerprints using Open Babel. In Box 2, we provide directions to calculate TCs between every type of fingerprint that has been calculated by implementing the relevant directions in this subsection of the PROCEDURE, as well as the next. This option is useful for calculating the TC between the interaction profile, target fingerprints and ADE fingerprints.  crItIcal Figure 5 illustrates the general workflow for the generation of M 2 . 6| By using the 'Wash' module in the MOE software, disconnect group I metals in simple salts and keep only the largest molecular fragment. Add hydrogen atoms to the structures and homogenize the protonation statei.e., consider all the molecules to be in a neutral state. Save the data in a new field in the file.  crItIcal step It is important to preprocess the structural data using the Wash module to avoid possible problems with the structure of the molecules. By implementing this step, researchers make sure that the molecular structures are suitable for fingerprint calculation.
7| To calculate MACCS fingerprints, open
Compute→Fingerprint in the data file window and select FP:MACCS and the field in which to apply the calculation-i.e., in the present case, the name of the field with the molecules that have already been preprocessed in Step 6.  crItIcal step Although in Steps 5-7 researchers are directed to calculate 2D MACCS fingerprints because they showed good results in previous studies [6] [7] [8] , other types of molecular fingerprints could also be calculated. As an example, researchers can calculate pharmacophoric fingerprints or typed atom distance fingerprints weighed with information related to atom types and distances (atom types: acid, basic, hydrogen bond donor or acceptor, hydrophobic). This type of fingerprinting procedure could capture better the similarity between two drugs when a particular charged group could be important for the interaction with the receptor (i.e., the bioisosteric replacement of carboxylate moiety by tetrazole motif, both with anionic characteristics). In this case, the protonated or deprotonated state of a drug, rather than its neutral state, would be considered to define the ionization state.
8|
Use the 'Fingerprint Cluster' module in MOE to calculate the TC, and thus measure the similarity between the different fingerprints. Save the resulting matrix file containing the similarity between molecules. Each cell in this file represents the similarity between the relevant pair of drugs.
9|
Use the 'sim_matrix2txt.svl' script in MOE to convert the similarity matrix constructed in Step 8 from binary to ASCII format. For this purpose, after opening the .svl file with MOE upload the database with the molecular structures (Step 5); next, upload the matrix file that you want to convert, and save the similarity matrix output as a .txt file. Please note that the final similarity matrix contains the TC between the drugs in an inverted scale (0 means maximum similarity). We recommend inverting the matrix at this point so that the TC spans values between 0 (maximum dissimilarity) and 1 (maximum similarity).
10|
Introduce 0 values in the matrix diagonal. Name this matrix M 2 .  crItIcal step As the method is based on matrix multiplication and maximization, the values in the diagonal of the matrix need to be set to 0 to avoid the growth of data noise caused by the 'similarity' of drugs with themselves.
Step 1
Steps 2 and 3
Step 4 12| Construct the final IPFs retaining only the vector position numbers for each drug. This is an efficient way to represent a sparse binary vector. Through this process, the researcher will calculate the IPFs for all the drugs included in the study. Save the file as .txt.
13|
Read the .txt file containing IPFs using MOE, and repeat the process described in Steps Figure 7 .
14| Download the DrugBank database containing target information. As we have done, we recommend putting together information on the target, enzyme, transporters and carriers in a unique target database. In the construction of the target database, eliminate repeated targets present in the different databases. Eliminate other redundant information from the different databases. Specifically, we suggest that the same target belonging to different species or organisms be considered as a unique case (single target).
15|
Similarly to Steps 11 and 12, list the targets for each drug in the study as a vector, and calculate the target fingerprints for all the drugs. The approach is the same, but instead of considering drug interactions in each bit position you now use targets for each bit vector position. Calculate the TC and M 2 as in Steps 8-10. Alternatively, use the script described in Box 2 to calculate the TC between fingerprints.
calculation of similarity measures and tc between drugs (matrix M 2 ): aDe fingerprints • tIMInG <1 h  crItIcal The workflow for the calculation of ADE fingerprints is detailed in Figure 7 .
16| Download the SIDER database (see MATERIALS), which contains information about marketed medicines and adverse drug reactions.
17|
Similarly to Steps 11 and 12, list the adverse reactions for each drug in the study as a vector that codifies the presence (1) or absence (0) of the adverse reactions in different bit positions. Calculate the ADE fingerprints for all the drugs included in the initial M 1 according to the procedure described previously for IPFs (Steps 11-13). Calculate TC and M 2 as in Steps 8-10 (or according to the directions in Box 2).
? trouBlesHootInG calculation of matrix M 2 using 3D pharmacophoric shape screening • tIMInG <5 d  crItIcal The workflow for 3D pharmacophoric shape screening is detailed in Figure 8 .
18|
Read the .sdf file previously downloaded (Step 5) with drug structure information from DrugBank using the Schrödinger package (http://www.schrodinger.com). 19| Preprocess the data using the LigPrep module in Schrödinger. Select in the module the option to optimize the molecular structures with OPLS_2005 force field implemented in Schrödinger. In the LigPrep module, select the option to generate the protonation state at pH = 7.0 using 'Ionizer' in Schrödinger. Retain the molecule with the largest number of atoms. Retain only the specified chiralities obtained from DrugBank, generating a maximum of three enantiomers in the case of chiral centers for which absolute chirality is unknown. Save the output file as a .mae file.  crItIcal step Although chirality information about the bioactive conformations of drugs is provided by DrugBank, some drugs have multiple unspecified chiral centers. As the generation of all possible enantiomers could substantially increase the computational cost of subsequent steps, we recommend retaining only a maximum of three enantiomers.
? trouBlesHootInG 20| Perform a conformational analysis for all the drugs. Select the force field and the inclusion of nonsolvent (vacuum)/ solvent (i.e., water) in the calculation. Select the nonbonded cutoff distances for hydrogen bond, van der Waals and electrostatic contributions. Choose a minimization method, convergence and number of iterations. Select the conformational search method and related parameters. As an example, Box 4 shows some parameters that can be used to run conformational analysis with the 'Macromodel' module from the Schrödinger package. Please note that we recommend running the conformational analysis using water as a solvent to diminish intramolecular interactions and to obtain drug conformations that are more representative of the biologically active ones than those obtained in vacuum.
? trouBlesHootInG
21|
In the output file containing the results from the conformational analysis, retain only the global minimum energy structure for each molecule as a template for the next modeling step and save the file as .mae. Please note that, although for simplicity only one conformation for molecule is taken into account as a template for the next steps of the PROCEDURE, a more complex system could be generated by considering different stable conformations for each molecule.
22|
Use the minimum energy structure for each molecule as a template for shape screening calculations using the Schrödinger package (Phase, version 3.3; http://www.schrodinger.com/). To run the calculation, upload to the Shape screening module the .mae database generated in Step 21 containing the calculated 3D structures of each drug (database 1). Upload the .mae file generated in Step 19 to the 'Shape' screening module with the molecules you want to screen (database 2). Select the pharmacophoric approach for volume scoring. Select the option to generate a maximum number of 500 conformers for each drug in the database 2 and run the calculation. The calculation will align the drug conformations in database 2 to each 3D molecular structure (templates) in the database 1 providing a similarity scoring (Phase Sim property). Save the output as a .mae file.
23| Export the output from the previous step as .txt and import it in Excel. For cases in which the template structure of a drug (database 1) is compared with different enantiomers of other drugs (a maximum of three enantiomers had been generated in Step 19 for drugs with multiple undefined chiral centers) or with different protonation states, select the pair with highest 3D similarity scoring (Phase Sim property). Transform the list of drugs with the name of drug A, name of drug B and the 3D similarity scoring (Phase Sim property) into a similarity matrix M 2 . As an example, it is possible to list the name of the drugs in a column and in a row of an Excel worksheet, to concatenate the names in each corresponding cell of the matrix extension Step 11
Step 12
Step 13
and to substitute the concatenated names by other code (i.e., the 3D scoring in this case) using a similar script (see Excel Forum, MS Office Application Help; http://www. excelforum.com), as described in Figure 4 .
Generation of the new set of potential DDIs: matrix M 3 and association of the DDI effects to the list of DDI candidates • tIMInG <10 h for 5 M 3 matrices 24| Multiply M 1 by M 2 , retaining only the highest value in the array multiplication in each cell. Although in each cell in the matrix different values could be obtained from all the possible pairs for one drug, retain only the maximum value in the array cell representing the interaction with the highest TC value and the maximum similarity to a DDI in the reference standard (see Fig. 9 for more details of the process in an Excel worksheet):
Box 4 | Conformational search options
Herein are some parameters that can be used in Macromodel to carry out a conformational analysis. The use of constraints or substructures is not included. Please note that the timing of this analysis is highly dependent on the number and complexity of the molecules. Step 20
Potential
Steps 21 and 22
Step 23  crItIcal step As M 12 is not symmetric (Step 24), this step should be carried out to make sure that the interactions drugi-drugj and drugj-drugi are weighed by the same TC interaction score.
27|
Use the function '=concatenate' in Excel to bind drugi, drugj and the TC score.
28| List all the DDIs generated by the model, divide them into three columns (name of the first drug, name of the second drug and TC interaction score) and sort them in terms of decreasing TC score.
29|
Eliminate the candidates extracted from the matrix diagonal that represent interactions of drugs with themselves. Please note that in our example (see ANTICIPATED RESULTS), we used 928 drugs and 9,454 interactions (18,908 if including interactions i-j as well as j-i). The total number of possible DDIs generated in a matrix of 928 × 928 drugs is 860,256 'doubled' DDIs (after removing 928 DDIs representing drugs' interactions with themselves). If only unique interactions are taken into account, the total number is 430,128 DDIs.
30|
Associate the DDI effects from the DDI reference standard with the new potential DDIs. To perform this task, link the DDIs extracted from M 3 to the initial source in M 1 in terms of DrugBank drug pairs associated with the pharmacological effects caused by the interaction (Fig. 10) . Through this operation, a researcher will ideally obtain a DDI multitype model that provides information not only on whether two drugs may interact but also on the possible biological effect produced by the interaction.  crItIcal step This step is very useful in decision-making, as all the information provided by the initial DDI source can be linked to the DDI candidate. In fact, the protocol as designed is able to point out the clinical importance of the DDI candidate based on the clinical significance of the DDI source in the DrugBank reference standard. However, an alternative option would be to introduce a weight parameter in M 1 that quantifies severity, frequency or clinical importance of the DDI outcome. Implementing this option could lead to a system that prioritizes interactions with clinically important associated adverse effects over interactions with outcomes rated as not severe. For instance, some severe adverse events produced by the interactions, such as heart failure or rhabdomyolysis, could obtain a higher score by the model than effects such as muscle pain.
combining the results in a complex model • tIMInG <5 min  crItIcal The five DDI scores obtained through the use of five different similarity measures can be combined in a unique DDI score (Fig. 11) . In this subsection of the PROCEDURE, the results of combining the five DDI scores are shown with principal component analysis (PCA) using the STATISTICA software, although other data mining, statistical techniques or software can be used to integrate the complex model. 
31|
Collect the information related to the five DDI scores (provided by the five M 3 matrices) and save the resulting file in Excel format (.xlsx). Read the .xlsx file with STATISTICA. In the 'factor analysis' module, select the five variables using 'principal components' as the extract method, and set the number of factors that will be extracted and the minimum eigenvalue (in our example, number of factors = 1, minimum eigenvalue = 1). The calculation will generate a new and unique factor score or DDI score.  crItIcal step In this protocol, we direct readers to implement an unsupervised method with no labeled training data (i.e., without labeling the DDIs as positives or negatives), and to train or select the best variables that explain the data. We take this approach to try to avoid an excessive contribution to the final model by a DDI score that better performs in a training run of the PROCEDURE but that would contribute to a lesser extent to the generation of an innovative final model. The number of factors or principal components extracted from the initial variables (i.e., in our case the five DDI scores provided by the five M 3 matrices (Step 31)) will depend on the data and the percentage of the variance of the initial variables (the five DDI scores) explained by each additional factor. The intention is to account for as much of the variance of the initial variables as possible using fewer components or factors. As an additional criterion, in this protocol only factors with eigenvalues >1 are retained 26 . In the example application covered in the present PROCEDURE, only one factor was extracted, as a second factor showed an eigenvalue lower than the preestablished cutoff (>1). A summary of the results of the actual output in the example implementation is shown below: 
33|
Save the file produced in Step 32 as .txt, which contains the DDIs extracted from M 3 (Steps 24-30), the TC (scoring associated to each interaction) and the true and false positive labels previously described.
34| Import the .txt file just generated in MOE and save it in .mdb format.
35| Load the roc_plot.svl script with MOE and read it at the Scientific Vector Language (SVL) command line:
36|
Select the true or false positive labels as an activity field and the TC scoring variable as a prediction field. 37| Plot and report the ROC results (i.e., the AUROC). Please note that the AUROC can alternatively be calculated using the open-source software R according to the directions in Box 3. The interpretation of the results from this step is provided and discussed in the ANTICIPATED RESULTS.  crItIcal step It is convenient to sort the candidates according to TC scoring before plotting the ROC.
? trouBlesHootInG Troubleshooting advice can be found in table 2.
• tIMInG Steps 1-4, generation of the reference standard DDI database (matrix M 1 ): <4 h (timing in this part will also depend on the DDI database used as a reference standard, manageability and size extension) Steps 5-10, generation of M 2 using MACCS fingerprints: <1 h Steps 11-13, generation of M 2 using IPFs: <1 h Steps 14 and 15, generation of M 2 using target fingerprints: <1 h Steps 16 and 17, generation of M 2 using ADE fingerprints: <1 h Steps 18-23, generation of M 2 using 3D pharmacophoric approach: <5 d (depending on the number of molecules to be calculated and the potency and capacity of the computer) Steps 24-30, generation of five DDI predictors (five M 3 matrices): <10 h
Step 31, complex model generation: <5 min Steps 32-37, ROC curves: <5 min Box 1, using Python to calculate molecular fingerprints and TC between all drug pairs with Open Babel: <5 min Box 2, using Python to calculate TCs between fingerprints: <5 min Box 3, calculating AUROC via R software: <5 min Fig. 12 for ROC curve information for the six predictors).
As it was shown by our research group [8] [9] [10] , predictors obtained by following this protocol have great stability and robustness in cross-validation sets. However, to test the predictor, it is important to evaluate the performance of the system in external and independent test sets that include DDIs not contemplated in the initial reference standard database (the DrugBank database in the present PROCEDURE). In table 3, AUROC results for two different test data sets are reported: data from the US Department of Veterans Affairs (VA) 28 and the interactions described in Drugs.com (http://www.drugs.com/) for the top 25 drugs sold in 2012.
We also tested the potential of our protocol to detect differences in drug-specific interaction risks for drugs belonging to the same pharmacological category. We collected the DDIs described in the VA data for the top 25 drugs sold in 2012 (interactions not described in the initial reference standard). For each interaction, i.e., drugs i (top25)-j, we localized other drugs in the initial set in M 2 with the same anatomical therapeutic chemical (ATC) code as drug j. That way we collected an enriched set of possible DDIs that are specific to the pharmacological category chosen. We calculated AUROCs for the sets considering true positives (interactions described in VA data) and false positives (interactions not described in VA data). table 4 shows the AUROCs for the different models with different similarity measures. The protocol showed some potential to differentiate drug-specific DDI risks even in the same category of drugs. In this test, knowledge measures, such as IPFs, target fingerprints and ADE fingerprints, outperformed 2D and 3D molecular similarity measures. However, development of more complex systems with well-established DDIs and non-DDIs in the reference standard, and the use of machine learning methods, could be an alternative to implement DDI detectors covering all the pharmacological space and assessing different risk levels for drugs classified in the same pharmacological category.
Models developed through this protocol enable the researcher to extend the clinical or pharmacological effect from the DDIs in the reference standard to the new DDI candidates (Fig. 10) . As an example described in a publication from our 
